By halting the TIM-3/galectin-9 interaction in leukemic cells, sabatolimab has therefore the potential to limit this autocrine feedback loop, and may have a direct impact on leukemic cells, limiting their self-renewal and reducing cancer growth. This evidence concerns the gene HAVCR2 and cancer.